Role of available adjuvant therapies following surgical resection of atypical choroid plexus papilloma – a systematic review and pooled analysis

Amin Tavallaii M.D, MSc1*, Ehsan Keykhosravi M.D1, Hamid Rezaee M.D2, Camellia Kianbakht3

1. Assistant professor, Akbar children hospital, Neurosurgery Department, Mashhad University of Medical Sciences, Mashhad, Iran
2. Assistant professor, Neurosurgery Department, Mashhad University of Medical Sciences, Mashhad, Iran
3. Mashhad University of Medical Sciences, Mashhad, Iran

Corresponding Author’s name and current institution:
Amin Tavallaii, Assistant professor, Akbar children hospital, Neurosurgery Department, Mashhad University of Medical Sciences, Mashhad, Iran
Corresponding Author’s Email: tavallaeia@mums.ac.ir

ORCID identifier: 0000-0003-2486-2919
Neurosurgery department office, 5th floor, Akbar children’s hospital, Kaveh Blvd., Mashhad, Iran
P.O. Box: 9177897157

Authorship:

Conception and design: Amin Tavallaii
Acquisition of data: Amin Tavallaii, Ehsan Keykhosravi, Camellia Kianbakht
Analysis and interpretation of data: Amin Tavallaii, Hamid Rezaee
Drafting the article: Amin Tavallaii, Ehsan Keykhosravi
Critically revising the article: Amin Tavallaii, Hamid Rezaee, Camellia Kianbakht
Final approval: Amin Tavallaii, Ehsan Keykhosravi, Hamid Rezaee, Camellia Kianbakht

Acknowledgment: We would like to express our gratitude to the staff of the Clinical Research Development Unit of Akbar Hospital for their support throughout this review.
Abstract:

Background: Atypical choroid plexus papilloma is a recently introduced entity with intermediate pathological characteristics. These tumors are relatively rare and the optimal management of these tumors is a matter of debate. Therefore, we performed a systematic review and pooled analysis about the effects of adjuvant therapies upon outcome measures of these patients. We also compared these effects upon totally and partially resected tumors and pediatric and adult populations.

Methods: A systematic search of three databases based on inclusion/exclusion criteria was performed. Data extraction was separately performed by two authors, and the summarized data were presented in the form of tables. Pooled estimates of different outcome measures were calculated for each adjuvant therapy and presented separately for studies with pediatric, adult, or mixed populations.

Results: A review of 14 included studies consisting of 144 patients revealed the effect of adjuvant treatment on reduction of tumor recurrence, metastasis, and reoperation rates and increasing survival rates in patients with subtotal tumor resection. This advantage was not seen in the case of gross total tumor resection. Almost all outcome measures were more favorable in the pediatric population.

Conclusions: It can be concluded that whenever gross total resection is not feasible, the implementation of adjuvant therapy can improve the outcome and prognosis. In other cases, it should be decided on an individual basis. Also, more aggressive behavior and higher rates of recurrence and mortality in the adult population suggests the consideration of more aggressive adjuvant treatments for adult patients.

Importance of the study: Atypical choroid plexus tumor is a relatively new histopathologic entity that comprises a small percentage of choroid plexus tumors and is considered as an intermediate entity between choroid plexus papilloma and carcinoma. Because of the rarity and recent introduction of these tumors in the literature, there is no consensus about their optimal management following gross total or subtotal surgical resection. Therefore, performing a pooled analysis on the limited available data in the literature can shed a light on this controversial issue in the management of these rare tumors.

Key Words: Atypical choroid plexus papilloma, Adjuvant, Chemotherapy, Radiotherapy, Chemoradiation
Key points:

- Atypical CPP has more aggressive behavior in the adult population compared to the children.
- Adjuvant treatment is recommended following subtotal resection of atypical CPP.
- Adjuvant treatment after total resection should be decided on a case by case basis.
Introduction:

Choroid plexus tumors (CPTs) are rare CNS tumors and account for 0.5-0.6% of all intracranial neoplasms in all ages. These tumors are more common in the pediatric population constituting about 2-4% of all pediatric CNS tumors. These tumors are most commonly located within the lateral ventricle and the fourth ventricle in children and adults respectively, although there are reports of these tumors located in unusual locations such as the third ventricle or Luschka foramen. CPTs were initially classified as WHO grade I choroid plexus papilloma (CPP) and WHO grade III choroid plexus carcinoma (CPC). The presence of any four of the malignant characteristics including brisk mitotic activity, nuclear pleomorphism, high cellularity, blurring of the papillary growth pattern, and necrosis leads to the diagnosis of CPC. The classification of CPTs into CPP and CPC did not cover few tumors with more neoplastic features than can be seen in CPP and not enough neoplastic features to be classified as CPC. This resulted in the coining of the term atypical choroid plexus papilloma (aCPP) as an intermediate entity. After reporting of higher mitotic activity as an atypical feature of choroid plexus papillomas that can affect tumor recurrence rate in a case series, atypical choroid plexus papilloma was defined as a new entity and classified as grade II by the WHO in 2007. The histopathologic appearance of aCPP is similar to CPP but with the presence of more than two mitoses in the high-power field (HPF). Recently, epigenetic characteristics of these tumors such as DNA methylation signature or TP53 somatic mutations are the focus of researchers trying to classify these tumors based on genetic profiles rather than histopathologic characteristics and to present a classification with more prognostic value.

The role of adjuvant therapies in the management of CPTs is controversial but the most debate in this regard is about the role of adjuvant therapy in aCPPs which is a relatively newer entity with few cases reported in the literature. For CPP, it is widely accepted that radical surgical removal is the most ideal therapy and no further adjuvant therapy is recommended. Because of the rarity of two other subtypes of CPTs, currently implemented therapeutic strategies are based on case reports, and a few larger case series and the optimal management of these tumors are a matter of debate. Nevertheless, adjuvant therapy in forms of chemotherapy or chemoradiation has a more established role in the management of CPC with reports of a significant increase in overall survival of affected patients following these treatments. In both CPC and aCPP, complete tumor resection seems to significantly improve the prognosis. Whether adjuvant therapies have the same positive effects on outcome measures of aCPP patients as they are reported to have on CPC patients is not demonstrated up to now. We also do not exactly know whether these therapies should be recommended to all aCPP patients or be reserved for subtotally resected aCPP tumors. Therefore, we decided to
perform a systematic review and pooled analysis of available data in the literature about the effects of different adjuvant therapies upon outcome measures of aCPP patients such as recurrence rate, CSF dissemination, or metastasis and overall or event-free survival rates. We also tried to compare these effects upon totally and partially resected tumors to provide clues to answer the aforementioned controversies.

Materials and Methods:

Literature search and screening:

This systematic review is conducted based on MOOSE reporting guidelines for systematic reviews and meta-analyses of observational studies. A comprehensive search strategy was planned based on our predefined PICO (Population, Intervention, Comparator, Outcome), including different spellings of “atypical choroid plexus papilloma” AND “Adjuvant” as keywords (supplementary material 1). A search of available literature was performed using PubMed, Scopus, and Cochrane library databases. Inclusion criteria were as follows: Clinical trials (randomized or non-randomized) and observational studies (cohorts, case series, case reports, and case-control studies) that include participants with a definite histopathologic diagnosis of atypical choroid plexus papilloma (WHO grade II) AND report radiographic outcome or indicate overall or event-free survival rates. Defined exclusion criteria were as follows: (1) Case reports presenting a single case, letters, reviews, conference abstracts, and book chapters (2) Animal and lab studies (3) Multiple studies published by the same author on the same population (all are excluded except the most complete and most recently published article) (4) Studies without available full text (5) Studies written in a language other than English.

Upon completion of the database search according to search strategy, titles and abstracts were extracted and authors and journal names were hidden to reduce bias. Two researchers independently and blindly screened extracted abstracts for eligibility according to inclusion and exclusion criteria. Any disagreement was resolved by discussion and a third researcher was consulted if researchers failed to achieve an agreement. Full texts of eligible studies were retrieved and underwent the same screening process to include eligible full-text articles. Bibliographic data of enrolled articles were checked for relevant articles to be added to the database.

Data extraction:

The extraction of data was conducted by two researchers independently and blindly using a pre-designed data extraction form. Data extraction was focused on study characteristics (study type, sample sizes, types of adjuvant treatments, follow-up durations), demographics of the study population, tumor location, extent of resection, details of outcome measures (radiologic recurrence/progression, remission rates, reoperations,
postoperative metastasis/dissemination), survival rates (overall and event-free survival), conclusions and suggestions. In case of any critical missing data, the corresponding author(s) were contacted for supplementary data. Any discrepancy between two researchers was resolved through discussion and a third researcher was consulted if researchers failed to achieve an agreement.

**Statistical analysis:**

Extracted data were inserted into predesigned tables for analysis. Because of the observational nature of available studies in form of cohorts and small case series with available individual patient data in most of the studies, we decided to perform a pooled analysis of available individual patient data by calculating means and rates in studies with pediatric, adult and mixed populations separately as well as measuring overall pooled estimates for the whole cohort of patients. We also divided patients with available individual data regarding the extent of tumor resection to gross total resection (GTR) and subtotal resection (STR) groups and once more calculated outcome measures and survival rates within these groups to control the influence of this confounding factor on results.

**Results:**

**Included studies:**

Search in different databases revealed 273 studies. After excluding non-English articles and screening titles and abstracts, 41 full-text articles were screened for eligibility. Finally, 14 studies were approved for enrollment into review including seven retrospective cohorts\(^{13,26-31}\), one prospective cohort\(^{15}\), and six case series\(^{14,32-36}\) (Figure 1). A summary of the included studies is presented in Table 1.

**Demographic data:**

There was a total of 144 patients with atypical choroid plexus papilloma including 107 patients who had received no adjuvant treatment, 24 patients who had been treated with chemotherapy postoperatively, and 8 and 5 patients who had undergone chemoradiation and radiotherapy respectively. Eight of the studies included pediatric patients\(^{13-15,27,29,30,33,36}\), and only two studies totally consisted of the adult patient population\(^{28,32}\). Also, four studies had a mixed pediatric and adult population\(^{26,31,34,35}\) with only one of them providing individual patient data for separate data extraction for the pediatric and adult populations\(^{31}\) (Table 1). To prevent readers from getting confused by these heterogeneous types of studies with different included populations, we
developed a strategy to demonstrate the results of these populations separately within tables. Of course, we also calculated the pooled estimates for the total included patient population. Ages of patients ranged from 0-16 years (mean: 1.9), 20-71 years (mean: 46.5), and 0-55 years (mean: 22.8) for pediatric, adult, and mixed populations respectively. Overall, no gender predilection was seen in all included patients (M/F: 1.08) although, in the adult population, the M/F ratio of 1.66 was calculated (Table 1).

**Pre-operative imaging findings:**

Interestingly, the most common tumor location in both pediatric and adult populations was the lateral ventricle, followed by the third ventricle and fourth ventricle in decreasing order but, in the mixed population, tumor location within the fourth ventricle was slightly more common than the lateral ventricle. Overall, in all included patients lateral ventricle was the most common location for aCPP followed by third and fourth ventricles. Radiologic evidence of preoperative dissemination or metastasis was only seen in five percent of the pediatric population which was equivalent to three percent of total included patients with aCPP (Table 2).

**The extent of resection:**

In the pediatric population, GTR was achieved in 74% of patients but aCPP tumors in adult and mixed populations were less amenable to gross total resection with 67% and 57% GTR rates respectively. Also, in all 144 patients, GTR was feasible in 69% of cases (Table 2).

**Adjuvant treatment protocols:**

Amongst the 14 included studies, the overall chemotherapy regimen or radiotherapy protocol had been indicated in only four studies\(^{15,29,31,34}\). Even in these four studies, the significant details of the adjuvant treatment protocol were missing. The mostly used chemotherapeutic agents were Etoposide, Vincristine, Cisplatine, Cyclophosphamide, or Ifosfomide but other agents such as Carboplatine or Thalidomide were also mentioned. No dosing data was available for these agents. The most commonly used radiotherapy protocol was local brain radiation with 54Gy (30 fractions of 1.8Gy) for non-metastatic tumors and craniospinal irradiation with 35.2Gy (22 fractions of 1.6Gy) and a local brain boost up to a total of 54Gy for metastatic tumors. Unfortunately, this detailed data was only available in three of the included studies, one of which included the pediatric patients and the two other studies consisted of mixed adult and pediatric patients\(^{15,31,34,37}\).
Radiologic outcome:

Pooled estimates of mean follow up duration for all included patients were 34.7 (1-190), 56.8 (3-119), 60 (3-84), and 44.4 (39-66) months for no adjuvant, chemotherapy, radiotherapy, and chemoradiation cohorts respectively with a calculated overall estimate of 40.5 months for the whole review cohort. Details of follow-up durations in each population are separately demonstrated in Table 2. An average of 8% of patients who had received no adjuvant therapy had shown signs of tumor progression or recurrence in the follow-up period. Interestingly these rates were 33%, 25%, and 20% for patients who had treated with chemotherapy, radiotherapy, or chemoradiation as an adjuvant, respectively (Table 3). These conflicting results seemed to be due to the potential confounding effect of the extent of resection which is comprehensively discussed in the following sections. Recurrence rate was considerably higher in the adult population compared to pediatric patients in almost all treatment arms. Overall mean time to recurrence was 35 months with longer times for patients who had received no adjuvant treatment (31 months) compared to patients who had been treated with various adjuvant treatments. Similar to recurrence rates, these findings seem to be confounded by the extent of tumor resection. In the pediatric population, tumor dissemination/metastasis has occurred in one patient with a subtotally resected tumor despite postoperative chemotherapy. Similarly, one of the adult patients has experienced postoperative dissemination/metastasis following subtotal tumor resection without any further adjuvant treatment. Generally, 14% of patients in the no adjuvant cohort had been undergone reoperation in the follow-up period while the pooled estimates of reoperation rates were 33% and 20% for chemotherapy and chemoradiation cohorts. The overall estimated rates of complete remission for no adjuvant, chemotherapy, and chemoradiation cohorts were 76%, 65%, and 71% respectively. All these data are presented in full detail for each cohort and each patient population in Table 3.

Survival rates:

Different measures were used by included studies to report the survival rates including 2-years overall survival (OS), 5-years OS, 2-years event-free survival (EFS), and 5-years EFS. In order to be able to include most of these measures in the pooled analysis, we selected the 2-years OS and EFS as our measures of interest. In cases in which 5-years survival rates were reported to be 100%, this rate was also considered for 2 years survival rate. As a result of this strategy, in the pediatric population, a 2-years OS of 93% was calculated for no adjuvant group while the patients who had received adjuvant therapies had shown a 2-years OS of 100%. This was also seen in the adult population with 2-years OS rates of 71% and 100% for no adjuvant and
chemotherapy/radiotherapy groups respectively. A complete array of calculated pooled estimates for OS, EFS, and mortality rates of each treatment strategy in each age group is provided in Table 4.

Outcome measures considering the extent of resection:

Most of the included studies had followed the strategy of implementing no adjuvant treatment for patients with gross total removal of the tumor and reserving chemotherapy, chemoradiation, or radiotherapy for patients with subtotal tumor resection. Only in three studies, initiation of adjuvant treatment was not based on this strategy and it was decided on an individual basis. As can be seen, this can be a potential confounding factor in the comparison of outcome measures between patients who had received no adjuvant treatment and those who had been treated with various adjuvant therapies. So, we divided the patients with separately available outcome data for various adjuvant therapies to GTR and STR groups and calculated the outcome measures for these groups separately (Supplementary material 2). In both GTR and STR groups, the mortality rate was lower in all patients that had received adjuvant therapies compared to the patients without any adjuvant treatment. Similarly, adjuvant therapies also resulted in a higher overall survival rate in both STR and GTR groups. Although the pooled estimate of overall survival for patients who had received chemotherapy in the STR group was slightly lower compared to patients who had not received any adjuvant therapies. An almost similar pattern was seen in pooled estimates of EFS. Another interesting finding was the considerable decrease in estimates of radiologic recurrence and rate of postoperative tumor dissemination/metastasis following adjuvant therapies in the STR group while there was not such an effect observed in the GTR group that is a clear approval of the presumed role for the extent of resection as a confounding factor (Figure 2).

Discussion:

The role of adjuvant therapies in the management of CPTs is controversial but the most debate in this regard is about the role of adjuvant therapy in aCPPs which is a relatively newer entity with fewer cases reported in the literature. Because of the rarity of aCPPs, currently implemented therapeutic strategies are not based on high-level evidence and the optimal management of these tumors is still a matter of debate. While it seems that complete tumor resection significantly improves the prognosis, it is not clearly demonstrated whether the adjuvant therapies have the same positive effects on outcome measures of aCPP patients as they are reported to have on CPC patients. It is also controversial whether these adjuvant therapies should be recommended to all aCPP patients or be reserved for subtotally resected aCPP tumors. In our review, we tried to answer these questions by pooling the available data in the literature and presenting a higher level of evidence.
Preoperative and operative parameters:

As we know, CPTs in general, are more commonly seen in the supratentorial and infratentorial regions in the pediatric and adult population, respectively. As an interesting finding of this review, the most common location of aCPP was the lateral ventricle followed by third and fourth ventricles in both pediatric and adult populations. This can be an important finding from an epidemiologic and diagnostic point of view.

Preoperative metastasis is not a rare finding in CPC but its incidence in aCPP patients is unknown. In this review, only one study reported 5 out of 24 patients to have preoperative metastasis, and this unusually high rate of metastasis compared to other included studies may be a result of referral or selection bias and should be considered as an outlier.

Gross total resection of CPPs is almost always feasible given the fact that these tumors do not invade surrounding brain parenchyma. On the contrary, invasion to the adjacent tissue is common in CPCs and these tumors are less amenable to GTR. As can be seen in this review GTR rate of aCPPs falls somewhere in between with an overall GTR rate of 69% for the whole review cohort. It is also evident that the GTR/STR ratio is lower in the adult population compared to pediatric patients.

Outcome measures:

In this review, the mean follow-up duration of patients who had received adjuvant therapies was higher than patients without any adjuvant treatments but even in these patients with no adjuvant treatment, the mean follow-up duration was long enough (34.7 months) to ensure a reliable estimate of outcome measures.

In the whole review cohort, an eight percent recurrence rate was calculated for patients who had not received any adjuvant treatment. However, after dividing the patients into two GTR and STR groups based on the extent of resection, all patients in the STR group had shown recurrence without receiving any adjuvant treatment while this rate was considerably lower (10%) in the GTR group. This underlines the extent of resection as one of the most important prognostic factors of patients with aCPPs similar to other grades of choroid plexus tumors.

In this review, as the result of a larger sample size compared to available case series and cohorts in the literature we were able to divide the review cohort to GTR and STR groups to control the confounding effect of the extent of resection on outcome measures. As can be seen in primary results, the adjuvant cohort paradoxically demonstrates higher rates of recurrence/progression, reoperation, and partial remission compared to no adjuvant cohort but, interestingly after controlling for the extent of resection as a potential confounding factor, the considerable effect of adjuvant treatment in the reduction of recurrence/progression,
metastasis/dissemination, and reoperation rates is evident. This is also true for survival rates with a clear survival advantage (both OS and EFS) of the adjuvant cohort over the no adjuvant cohort.

Even in the GTR group, there were few positive effects on outcome measures (although brief) observed for adjuvant therapy. For example in patients who had received adjuvant treatments (except radiotherapy) rate of complete remission was higher especially for chemoradiation. Also, patients who had received adjuvant treatments (despite GTR) had shown lower mortality rates and higher OS. In the GTR group, only two patients had received radiotherapy alone as the adjuvant treatment which is a statistically small sample size and the inconsistency of results for these two patients with other results of the adjuvant cohort is related to this small sample size and can be considered as an outlier.

**Epigenetic profile:**

There are recent interesting reports available in the literature that show the correlation between the epigenetic profile of the choroid plexus tumors and patient outcomes. In an attempt to present an epigenetic-based classification of choroid plexus tumors with prognostic value, Thomas et al used the DNA methylation hierarchical clustering technique which resulted in three clinically distinct subgroups. Methylation clusters 1 and 2 have consisted of CPP and aCPP patients of the pediatric and adults populations respectively. Whereas methylation cluster 3 consisted of all three histological subgroups of the CPTs (CPP, aCPP, and CPC) in the pediatric population. Patients in cluster 3 had significantly lower overall survival and higher tumor progression. Interestingly, the prognosis and outcome of patients with aCPP can be classified as low risk (clusters 1 and 2) and high risk (cluster 3). TP53 mutation status was also introduced as a prognostic factor. All TP53 mutations had been seen in patients categorized as cluster 3 and no patient in clusters 1 or 2 had shown TP53 mutation. Unfortunately, the epigenetic profile was not addressed in any of the included studies and we were not able to investigate these findings in our review.

**Pediatric vs adult population:**

This is the first review which provides the opportunity to compare outcome measures of aCPP between pediatric and adult population. This separation of adult and pediatric population seems more important when we consider the differences in responses to and consequences of various adjuvant therapies between these two physiologically different populations. Interestingly, it seems that tumor recurrence/progression, postoperative metastasis/dissemination, and reoperation rate is generally higher in the adult population regardless of implemented adjuvant treatment strategy. Also, adult patients with aCPP seem to have a lower complete
remission rate, the extent of resection, OS, and EFS compared to the pediatric population. These findings underline the more aggressive behavior and less favorable outcome of adult patients. Therefore, older age can be suggested as a negative prognostic factor for aCPP.

**Strength and limitations:**

This is the first review dedicated specifically to the role of adjuvant treatment in the less-studied aCPP entity. We tried to perform a comprehensive and reliable review of the literature and to avoid errors or biases by involving two authors in critical steps such as article screening and data extraction. We also prepared this review according to standardized MOOSE reporting guidelines to augment its quality. Fortunately, the mean follow-up duration in all groups was considerably long enough which ensures reliable estimates of long-term outcomes. Another strength of our review is that we divided the review cohort into two separate age-based cohorts of adults and pediatric patients which resulted in the ability to compare the tumor characteristics and outcome measures between these two physiologically different populations. Certainly, we faced some limitations during the review process. Like many other entities of neurosurgery, almost all of the included studies are case series and retrospective observational studies with small sample sizes which impede the achievement of more reliable conclusions. Among 144 patients present in the whole review cohort, 107 patients had not received any adjuvant treatments while various adjuvant treatments had been implemented for the other 37 patients. This asymmetry in sample sizes of these two arms of our review is a limitation which is inevitable in the pooled analysis of case series and retrospective cohorts and a large size prospective study is needed to address this shortcoming.

**Conclusions:**

In this review, we have shown that the nature and behavior of aCPP are not the same in all patients with more aggressive behavior and higher rates of recurrence and mortality in the adult population compared to pediatric patients which recommend consideration of more aggressive adjuvant treatments for adult patients. We also demonstrated a clear advantage of adjuvant treatment in patients who had undergone STR in terms of decreasing the recurrence rate, metastasis, reoperation rate, and increasing the OS and EFS. Despite the small benefits of adjuvant treatments in patients who had undergone GTR, it can not be recommended to all these patients and it should be decided on an individual basis. The optimal adjuvant treatment for aCPP patients can not be concluded from this review and there is a significant gap in the literature about this entity which can be addressed by conducting a long-term prospective cohort with multiple treatment arms.
Compliance with ethical standards:

Conflicts of interest: Authors have no conflicting interest to disclose

Human participant or animal involvement: This is a systematic review of available data and there is no human participant or animal directly or indirectly involved in this study.

Informed consent or ethical approval: Because systematic reviews do not present individual data that can disclose patients’ identity, informed consent acquisition is not applicable. On the other hand, because systematic reviews use publicly available data for interpretation of results and do not include any interventions, institutional ethics approval was not obtained. However, all relevant aspects of ethics in the research were considered and followed throughout the study.

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
References:

1. Gupta N. Choroid plexus tumors in children. *Neurosurgery clinics of North America*. 2003; 14(4):621-631.

2. Patel S, Bhatnagar A, Wear C, et al. Are pediatric brain tumors on the rise in the USA? Significant incidence and survival findings from the SEER database analysis. *Childs Nerv Syst*. 2014; 30(1):147-154.

3. Bettegowda C, Adogwa O, Mehta V, et al. Treatment of choroid plexus tumors: a 20-year single institutional experience. *J Neurosurg Pediatr*. 2012; 10(5):398-405.

4. Jaiswal AK, Jaiswal S, Sahu RN, Das KB, Jain VK, Behari S. Choroid plexus papilloma in children: Diagnostic and surgical considerations. *Journal of pediatric neurosciences*. 2009; 4(1):10-16.

5.ogiwara H, Dipatri AJ, Jr., Alden TD, Bowman RM, Tomita T. Choroid plexus tumors in pediatric patients. *British journal of neurosurgery*. 2012; 26(1):32-37.

6. Tavallaii A, Keykhosravi E, Rezaee H. Telovelar approach for microsurgical resection of an unusually located choroid plexus papilloma in the luschka foramen of an infant – Case report and review of literature. *Interdisciplinary Neurosurgery*. 2020; 20:100693.

7. Rickert CH, Paulus W. Tumors of the choroid plexus. *Microsc Res Tech*. 2001; 52(1):104-111.

8. Jeibmann A, Hasselblatt M, Gerss J, et al. Prognostic implications of atypical histologic features in choroid plexus papilloma. *J Neuropathol Exp Neurol*. 2006; 65(11):1069-1073.

9. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. *Acta Neuropathol*. 2007; 114(2):97-110.

10. Pienkowska M, Choufani S, Turinsky AL, et al. DNA methylation signature is prognostic of choroid plexus tumor aggressiveness. *Clinical Epigenetics*. 2019; 11(1):117.

11. Thomas C, Sill M, Ruland V, et al. Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. *Neuro Oncol*. 2016; 18(6):790-796.

12. Kamar FG, Kairouz VF, Nasser SM, Faddoul SG, Saiakali IC. Atypical choroid plexus papilloma treated with single agent bevacizumab. *Rare Tumors*. 2014; 6(1):4687.

13. Passariello A, Tufano M, Spennato P, et al. The role of chemotherapy and surgical removal in the treatment of Choroid Plexus carcinomas and atypical papillomas. *Childs Nerv Syst*. 2015; 31(7):1079-1088.

14. Koh EJ, Wang KC, Phi JH, et al. Clinical outcome of pediatric choroid plexus tumors: retrospective analysis from a single institute. *Childs Nerv Syst*. 2014; 30(2):217-225.

15. Wrede B, Hasselblatt M, Peters O, et al. Atypical choroid plexus papilloma: clinical experience in the CPT-SIOP-2000 study. *Journal of neuro-oncology*. 2009; 95(3):383-392.

16. Sun MZ, Ivan ME, Oh MC, et al. Effects of adjuvant chemotherapy and radiation on overall survival in children with choroid plexus carcinoma. *J Neurooncol*. 2014; 120(2):353-360.

17. Lafay-Cousin L, Mabbott DJ, Halliday W, et al. Use of ifosfamide, carboplatin, and etoposide chemotherapy in choroid plexus carcinoma. *J Neurosurg Pediatr*. 2010; 5(6):615-621.

18. Sun MZ, Oh MC, Ivan ME, et al. Current management of choroid plexus carcinomas. *Neurosurg Rev*. 2014; 37(2):179-192; discussion 192.

19. Chow E, Reardon DA, Shah AB, et al. Pediatric choroid plexus neoplasms. *Int J Radiat Oncol Biol Phys*. 1999; 44(2):249-254.

20. Packer RJ, Perilongo G, Johnson D, et al. Choroid plexus carcinoma of childhood. *Cancer*. 1992; 69(2):580-585.

21. Pencalet P, Sainte-Rose C, Lellouch-Tubiana A, et al. Papillomas and carcinomas of the choroid plexus in children. *J Neurosurg*. 1998; 88(3):521-528.

22. Pierga JY, Kalifa C, Terrier-Lacombe MJ, Habrand JL, Lemerle J. Carcinoma of the choroid plexus: a pediatric experience. *Med Pediatr Oncol*. 1993; 21(7):480-487.

23. Strojan P, Jereb B, Popovic M, Surlan K. Successful therapy of choroid plexus carcinoma. *Pediatr Blood Cancer*. 2004; 43(2):179.
24. Wolff JE, Sajedi M, Brant R, Cuples MJ, Egeler RM. Choroid plexus tumours. Br J Cancer. 2002; 87(10):1086-1091.
25. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama. 2000; 283(15):2008-2012.
26. Menon G, Nair SN, Baldawa SS, Rao RB, Krishnakumar KP, Gopalakrishnan CV. Choroid plexus tumors: an institutional series of 25 patients. Neurology India. 2010; 58(3):429-435.
27. Serowka K, Chiu Y, Gonzalez I, et al. Central nervous system (CNS) tumors in the first six months of life: the Children's Hospital Los Angeles experience, 1979-2005. Pediatr Hematol Oncol. 2010; 27(2):90-102.
28. Turkoglu E, Kertmen H, Sanli AM, et al. Clinical outcome of adult choroid plexus tumors: retrospective analysis of a single institute. Acta Neurochir (Wien). 2014; 156(8):1461-1468; discussion 1467-1468.
29. Siegfried A, Morin S, Munzer C, et al. A French retrospective study on clinical outcome in 102 choroid plexus tumors in children. J Neurooncol. 2017; 135(1):151-160.
30. Zhou WJ, Wang X, Peng JY, et al. Clinical Features and Prognostic Risk Factors of Choroid Plexus Tumors in Children. Chinese medical journal. 2018; 131(24):2938-2946.
31. Hosmann A, Hinker F, Dorfer C, et al. Management of choroid plexus tumors-an institutional experience. Acta Neurochir (Wien). 2019; 16(4):745-754.
32. Bostrom A, Bostrom JP, von Lehe M, Kandenwein JA, Schramm J, Simon M. Surgical treatment of choroid plexus tumors. Acta Neurochir (Wien). 2011; 153(2):371-376.
33. Lam S, Lin Y, Cherian J, et al. Choroid plexus tumors in children: a population-based study. Pediatr Neurosurg. 2013; 49(6):331-338.
34. Bohara M, Hirabaru M, Fujio S, et al. Choroid Plexus Tumors: Experience of 10 Cases with Special References to Adult Cases. Neurol Med Chir (Tokyo). 2015; 55(12):891-900.
35. Cannon DM, Mohindra P, Gondi V, Kruser TJ, Kozak KR. Choroid plexus tumor epidemiology and outcomes: implications for surgical and radiotherapeutic management. J Neurooncol. 2015; 121(1):151-157.
36. Dash C, Moorthy S, Garg K, et al. Management of Choroid Plexus Tumors in Infants and Young Children Up to 4 Years of Age: An Institutional Experience. World Neurosurg. 2019; 121:e237-e245.
37. !!! INVALID CITATION !!! [Bohara, 2015 #133].
Legends:

**Figure 1** PRISMA chart describing the flow of the article screening procedure

**Figure 2** Bar charts demonstrating pooled estimates of various outcome measures following each adjuvant therapy separately calculated for GTR and STR groups

**Table 1** Summary of the included studies and demographic data of included patients separately for studies with pediatric, adult, and mixed populations (numbers in the parentheses present ranges and percentages). GTR: gross total resection, STR: subtotal resection

**Table 2** Summary of preoperative imaging findings, the extent of tumor resection, and follow-up duration of included studies separately for studies with pediatric, adult, and mixed populations (numbers in the parentheses present ranges and percentages). GTR: gross total resection, STR: subtotal resection

**Table 3** Summary of postoperative outcome measures following each adjuvant therapy calculated separately for studies with pediatric, adult, and mixed populations. CR: complete remission, PR: partial remission

**Table 4** Summary of survival rates following each adjuvant therapy calculated separately for studies with pediatric, adult, and mixed populations (numbers in the parentheses present percentages)
| Study                  | Study design          | Time period   | N  | Study groups (n)                                                                 | Mean age (Years) | Male n, (%) | Female n, (%) |
|-----------------------|-----------------------|---------------|----|---------------------------------------------------------------------------------|------------------|-------------|--------------|
| Wrede 2009 15         | Cohort (Prospective)  | 2000-2008     | 24 | No adjuvant (GTR) (15) Chemotherapy (STR) (5) Chemoradiation (STR above 3) (4)  | 0.6 (0-9)        | 12,(50%)    | 12,(50%)     |
| Serowka 2010 27       | Cohort (Retrospective) | 1979-2005     | 2  | No adjuvant (GTR) (1) Chemotherapy (STR) (1)                                  | 0.3 (0.2-0.3)    | 2,(100%)    | 0            |
| Lam 2013 33           | Case series           | 1973-2008     | 12 | No adjuvant (12)                                                               | 2.1 (0-6)        | 5,(42%)     | 7,(58%)      |
| Koh 2014 14           | Case series           | 1993-2012     | 7  | No adjuvant (7)                                                                | 0.6              | 4,(58%)     | 3,(42%)      |
| Passariello 2015 11   | Cohort (Retrospective)| 2000-2014     | 4  | No adjuvant (GTR) (2) Chemotherapy (STR) (2) No adjuvant (GTR:14/STR:6) (20) | 5 (0.6-16)       | 1,(25%)     | 3,(75%)      |
| Siegfried 2017 29     | Cohort (Retrospective)| 2000-2012     | 26 | Chemotherapy (GTR:3, STR:1) (4) Chemoradiation (GTR:1/STR:1) (2) No adjuvant | 1.9 (0-12)       | 14,(54%)    | 12,(46%)     |
|                      |                       |               |    | (GTR) (5) Chemoradiation (GTR) (10) Radiotherapy (STR) (1)                      |                  |             |              |
| Zhou 2018 30          | Cohort (Retrospective)| 2011-2016     | 17 | No adjuvant (GTR:14/STR:6) (20) Chemotherapy (GTR:3, STR:1) (4) Chemoradiation | 4.2 (0.6-14)     | 12,(70%)    | 5,(30%)      |
|                      |                       |               |    | (GTR) (10) Radiotherapy (STR) (1)                                               |                  |             |              |
| Dash 2019 36          | Case series           | 2010-2018     | 2  | No adjuvant (GTR) (2)                                                          | 0.2 (0.1-0.3)    | 2,(100%)    | 0            |
| Hosmann 2019 31       | Cohort (Retrospective)| 1991-2016     | 5  | No adjuvant (GTR) (5)                                                          | 0.7 (0.2-1.3)    | 2,(40%)     | 3,(60%)      |
| Pooled Estimates      |                       | 1973-2018     | 99 |                                                                  | 1.9 (0-16)       | 54,(54.5%)  | 45,(45.5%)   |
| Bostrom 2011 32       | Case series           | 1990-2008     | 2  | No adjuvant (2)                                                                | 37.5 (20-55)     | 1,(50%)     | 1,(50%)      |
| Turkoglu 2014 28      | Cohort (Retrospective)| 2002-2012     | 4  | No adjuvant (GTR) (2) Radiotherapy (STR) (2)                                  | ---             | ---         | ---          |
|                      |                       |               |    | No adjuvant (GTR:2/STR:1) (3) Chemotherapy (STR) (1) Radiotherapy (GTR) (2)    |                  |             |              |
| Hosmann 2019 31       | Cohort (Retrospective)| 1991-2016     | 6  | No adjuvant (GTR:2/STR:1) (3) Chemotherapy (STR) (1) Radiotherapy (GTR) (2)    | 49.6 (34-71)     | 4,(67%)     | 2,(33%)      |
| Pooled Estimates | 1990-2016 | 12 | 46.5 (20-71) | 5,(62.5%) | 3,(37.5%) |
|------------------|-----------|----|--------------|-----------|-----------|
| Menon 2010 36     | Cohort (Retrospective) | 1998-2009 | 4 | No adjuvant (3) Chemotherapy (1) | 22.1 (0.7 - 43) | 3,(75%) | 1,(25%) |
| Bohara 2015 34    | Case series | 1995-2014 | 3 | No adjuvant (GTR) (2) Chemoradiation (STR) (1) | 24.1 (0.5-46) | 0 | 3,(100%) |
| Cannon 2015 35    | Case series | 2004-2009 | 26 | No adjuvant (26) | 22.8 (0-55) | 11,(42%) | 15,(58%) |
| Pooled Estimates  | 1995-2014 | 33 | 22.8 (0-55) | 14,(42%) | 19,(58%) |
| Total Estimates   | 1973-2018 | 144 | 9.3 (0-71) | 73,(52%) | 67,(48%) |

Table 1 Summary of the included studies and demographic data of included patients separately for studies with pediatric, adult and mixed populations (numbers in the parentheses present ranges and percentages). GTR: gross total resection, STR: subtotal resection.
| Study                  | Tumor location | Preoperative metastasis | Extent of resection | Mean follow-up duration (m) |
|------------------------|----------------|-------------------------|---------------------|-----------------------------|
|                        | Lateral ventricle | 4th ventricle | 3rd ventricle | GTR | STR | Overall | No adjuvant Chemotherapy | Radiotherapy | Chemoradiation |
| Wrede 2009            | 20 (83%) | 1 (4%) | 3 (12%) | 5 (20%) | 15 (62%) | 9 (38%) | 30 (20-39) | 20 | 39 | --- | 39 |
| Serowka 2010          | 1 (50%) | 0 | 1 (50%) | 0 | 1 (50%) | 1 (50%) | 2 (1-3) | 1 | 3 | --- | --- |
| Lam 2013              | --- | --- | --- | 0 | 8 (67%) | 4 (33%) | 38 (21-56) | 38 (21-56) | --- | --- | --- |
| Koh 2014              | 6 (86%) | 0 | 1 (14%) | 0 | 7 (100%) | 0 | 69 | 69 | --- | --- | --- |
| Passariello 2015      | 4 (100%) | 0 | 0 | 0 | 2 (50%) | 2 (50%) | 90.7 (20-144) | 49.5 (20-79) | 114 | --- | --- |
| Siegfried 2017        | 22 (85%) | 0 | 4 (15%) | 0 | 18 (69%) | 8 (31%) | --- | --- | --- | --- | --- |
| Zhou 2018             | 12 (70%) | 4 (24%) | 1 (6%) | 0 | 15 (88%) | 2 (12%) | 12 (2-53) | --- | --- | --- | --- |
| Dash 2019             | 1 (50%) | 0 | 1 (50%) | 0 | 2 (100%) | 0 | 3 | 3 | --- | --- | --- |
| Hosmann 2019          | 3 (60%) | 0 | 2 (40%) | 0 | 5 (100%) | 0 | 61.4 (4-182) | 61.4 (4-182) | --- | --- | --- |
| **Pooled Estimates**  | 69 (79%) | 5 (6%) | 13 (15%) | 5 (5%) | 73 (74%) | 26 (26%) | 34.8 (1-182) | 22.3 (1-182) | 53.2 (3-114) | --- | 39 |
| Adult                 | 1 (50%) | 0 | 1 (50%) | 0 | 2 (100%) | 0 | 51 (28-74) | 51 (28-74) | --- | --- | --- |
| Bostrom 2011          | --- | --- | --- | 0 | 2 (50%) | 2 (50%) | 68.4 (48-84) | 68.4 (48-84) | --- | 68.4 (48-84) | --- |
| Turkoglu 2014        | 6 (100%) | 0 | 0 | 0 | 4 (67%) | 2 (33%) | 97 (3-190) | 137.2 (108-190) | 119 | 51.6 (3-49) | --- |
| Hosmann 2019          | --- | --- | --- | 0 | 8 (67%) | 4 (33%) | 79.8 (3-190) | 93 (28-190) | 119 | 60 (3-84) | --- |
| **Pooled Estimates**  | 7 (87%) | 0 | 1 (13%) | 0 | 8 (67%) | 4 (33%) | 79.8 (3-190) | 93 (28-190) | 119 | 60 (3-84) | --- |
| Mix                   | 2 (50%) | 2 (50%) | 0 | 0 | 2 (50%) | 2 (50%) | 26 (18-44) | 26 (18-44) | 24 | --- | --- |
|                | Bohara 2015 | Cannon 2015 | Pooled Estimates | Total Estimates |
|----------------|-------------|-------------|------------------|-----------------|
|                | 1 (33%)     | 2 (67%)     | 1 (33%)          | 100 (69%)       |
|                | 0           | 0           | 2 (67%)          | 44 (31%)        |
|                | 0           | 0           | 15 (58%)         | 40.5 (1-190)    |
|                | 1 (33%)     | 11 (42%)    | 11 (52-171)      | 34.7 (1-190)    |
|                | 96 (52-171) | ---         | 56.8 (3-119)     | 56 (3-84)       |
|                | 111 (52-171)| ---         | 62.4 (18-171)    | 44.4 (39-66)    |

Table 2 Summary of preoperative imaging findings, the extent of tumor resection, and follow-up duration of included studies separately for studies with pediatric, adult, and mixed populations (numbers in the parentheses present ranges and percentages). GTR: gross total resection, STR: subtotal resection.
| Study                  | Recurrence/Progression | Mean time to recurrence (m) | Postoperative metastasis | Reoperation | Radiologic outcome |
|-----------------------|------------------------|-----------------------------|--------------------------|-------------|--------------------|
|                       | Overall | No adjuvant | Chemotherapy | Radiotherapy | Chemoradiation | Overall | No adjuvant | Chemotherapy | Radiotherapy | Chemoradiation | Overall | No adjuvant | Chemotherapy | Radiotherapy | Chemoradiation |
| Wrede 2009            |         | 2          | 1            | 1            | 25          | 27         | 2          | 0          | 8           | 8           | 0           | 1         | 0          | 0          | 0           | 1          |
| Serowa 2010           |         | 0          | 0            | 0            | 0           | 0          | 0          | 0          | 0           | 0           | 0           | 0         | 0          | 0          | 0           | 0          |
| Lam 2013              |         | 0          | 0            | 0            | 0           | 0          | 0          | 0          | 0           | 0           | 0           | 0         | 0          | 0          | 0           | 0          |
| Koh 2014              |         | 0          | 0            | 0            | 0           | 0          | 0          | 0          | 0           | 0           | 0           | 0         | 0          | 0          | 0           | 0          |
| Passariello 2015      |         | 2          | 0            | 2            | 10          | 10         | 1          | 0          | 1           | 2           | 0          | 0         | 0          | 0          | 0           | 0          |
| Siegfried 2017        |         | 9          | 9            | 9            | 9           | 9          | 9          | 9          | 9           | 9           | 9          | 9         | 9          | 9          | 9           | 9          |
| Zhou 2018             |         | 0          | 0            | 0            | 0           | 0          | 0          | 0          | 0           | 0           | 0           | 0         | 0          | 0          | 0           | 0          |
| Dash 2019             |         | 1          | 1            | 1            | 1           | 1          | 1          | 1          | 1           | 1           | 1          | 1         | 1          | 1          | 1           | 1          |
| Hosmann 2019          |         | 0          | 0            | 0            | 0           | 0          | 0          | 0          | 0           | 0           | 0           | 0         | 0          | 0          | 0           | 0          |

**Pediatric**

| Study                  | Pooled Estimates |
|-----------------------|------------------|
|                       | 23% 5% 28% 25% 10 25 10 27 9 10 8 0 3% 28% 25% 100% 0 83% 17% 68% 32% 100% 0 71% 29% |

**Adult**

| Study                  | Pooled Estimates |
|-----------------------|------------------|
|                       | 42% 43% 100% 25% 8 14 0 0 33% 43% 100% 0 33% 0 100% 0 100% |

**Mixed**

| Study                  | Pooled Estimates |
|-----------------------|------------------|
|                       | 28% 40% 0 0 60 60 9 10 0 28% 40% 0 0 0 0 76% 18% 65% 35% 100% 0 71% 29% |

**Total Estimates**

| Study                  | Pooled Estimates |
|-----------------------|------------------|
|                       | 25% 8% 33% 25% 20% 35% 31% 10 27 5% 6% 7% 0 21% 14% 33% 20% 76% 18% 65% 35% 100% 0 71% 29% |

Table 3 Summary of postoperative outcome measures following each adjuvant therapy calculated separately for studies with pediatric, adult, and mixed populations. CR: complete remission, PR: partial remission
| Study                  | Overall Survival (OS) | Event Free Survival (EFS) | Mortality |
|-----------------------|------------------------|---------------------------|-----------|
|                       | Overall | No adjuvant | Chemotherapy | Radiation | Chemoradiation | Overall | No adjuvant | Chemotherapy | Radiation | Chemoradiation |
| Pediatric             |         |             |                |           |                |         |             |                |           |                |
| Wrede 2009 15         | 89%     | ---         | ---            | ---       | ---            | 83%     | ---         | ---            | ---       | ---            |
| Serowka 2010 17       | ---     | ---         | ---            | ---       | ---            | 1       | 0           | 0              | ---       | ---            |
| Lam 2013 33           | 83%     | 83%         | ---            | ---       | ---            | 2       | 2           | ---            | ---       | ---            |
| Koh 2014 14           | 100%    | 100%        | ---            | ---       | ---            | 0       | 0           | ---            | ---       | ---            |
| Passariello 2015 13   | 100%    | 100%        | 100%           | ---       | ---            | 0       | 0           | 0              | ---       | ---            |
| Siegfried 2017 29     | ---     | ---         | ---            | ---       | ---            | 1       | 1           | ---            | ---       | ---            |
| Zhou 2018 10          | 100%    | 100%        | 100%           | 100%      | ---            | 0       | 0           | 0              | 0        | 0              |
| Dash 2019 36          | ---     | ---         | ---            | ---       | ---            | 1       | 1           | ---            | ---       | ---            |
| Hosmann 2019 31       | 100%    | 100%        | ---            | ---       | ---            | 0       | 0           | ---            | ---       | ---            |
| Pooled Estimates      | 93%     | 93%         | 100%           | 100%      | 100%           | 6       | 4           | 1              | 0        | 1              |
|                       | (6%)    | (6%)        | (4%)           | (14%)     |                | (17%)   | (28%)       | (9%)          | (10%)    | (1%)           |
| Adult                 |         |             |                |           |                |         |             |                |           |                |
| Bostrom 2011 12       | 100%    | 100%        | ---            | ---       | ---            | 0       | 0           | ---            | ---       | ---            |
| Turkoglu 2014 28      | 100%    | 100%        | 100%           | ---       | ---            | 0       | 0           | ---            | 0        | ---            |
| Hosmann 2019 31       | 67%     | 33%         | 100%           | 100%      | ---            | 2       | 2           | 0              | 0        | ---            |
| Pooled Estimates      | 83%     | 71%         | 100%           | 100%      | ---            | 66%     | 57%         | 75%            | ---      | ---            |
|                       | (17%)   | (28%)       |                |           |                | (17%)   | (28%)       | (9%)          | (10%)    | (1%)           |
| Mix                   |         |             |                |           |                |         |             |                |           |                |
| Menon 2010 26         | 100%    | 100%        | 100%           | ---       | ---            | 0       | 0           | 0              | ---       | ---            |
| Bohara 2015 34        | 100%    | 100%        | ---            | 100%      | ---            | 0       | 0           | ---            | 0        | ---            |
| Cannon 2015 35        | ---     | ---         | ---            | 100%      | ---            | 3       | 3           | ---            | ---      | ---            |
| Pooled Estimates      | 100%    | 100%        | 100%           | 100%      | ---            | 100%    | 71%         | 60%            | ---      | 100%           |
|                       | (9%)    | (10%)       | (1%)           | (10%)     |                | (9%)    | (6%)        | (4%)           | (0%)     | (12%)          |
| Total Estimates       | 92%     | 90%         | 100%           | 100%      | 100%           | 71%     | 77%         | 100%           | 75%      | 100%           |
|                       | (9%)    | (10%)       | (1%)           | (10%)     | (1%)           | (9%)    | (6%)        | (4%)           | (0%)     | (12%)          |

Table 4 Summary of survival rates following each adjuvant therapy calculated separately for studies with pediatric, adult and mixed populations (numbers in the parentheses present percentages)
Figure 1

Identification

Database search (n = 524)

Records after duplicates removed (n = 273)

Excluded other languages (n = 17)

Screening

Title and abstracts screened (n = 256)

Studies excluded (n = 215):
- Non-relevant titles and abstracts (n = 213)
- No available full text (n = 2)

Eligibility

Full-text articles assessed for eligibility (n = 41)

Full-text articles excluded (n = 27):
- Non-relevant (n = 18)
- Reviews, commentaries and case reports: 9

Included

Studies included in review and analysis (n = 14):
- Cohort (Retrospective): 7
- Cohort (Prospective): 1
- Case series: 6
Figure 2

GTR GROUP

| METASTASIS DISSEMINATION | RADIOLOGIC RECURRENCE | MORTALITY | COMPLETE REMISSION | OS | EFS |
|--------------------------|-----------------------|-----------|--------------------|----|-----|
| 10.3                     | MA                    | 50        | 80.8               | 93 | 88  |

STR GROUP

| METASTASIS DISSEMINATION | RADIOLOGIC RECURRENCE | MORTALITY | COMPLETE REMISSION | OS | EFS |
|--------------------------|-----------------------|-----------|--------------------|----|-----|
| 33.3                     | 37.5                  | 28.6      | 57.1               | 86.1| 80  |

Legend: No adjuvant, Chemotherapy, Chemoradiation, Radiotherapy